New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn?

Clinical Microbiology and Infection

Volumn 23, Issue 10, 2017, Pages 704-712

  Wright, H ^a   Bonomo, R A ^b   Paterson, D L ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

Author keywords

Acinetobacter; Cefiderocol; Ceftazidime Avibactam; Colistin; Klebsiella; Meropenem Vaborbactam; Pseudomonas

Indexed keywords

AVIBACTAM; AVIBACTAM PLUS CEFTAZIDIME; AZTREONAM; BETA LACTAM; BETA LACTAMASE INHIBITOR; CEFIDEROCOL; CEFTOLOZANE; CILASTATIN PLUS IMIPENEM; ERAVACYCLINE; MEROPENEM PLUS VABORBACTAM; PLAZOMICIN; RELEBACTAM; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; GRAM NEGATIVE BACTERIUM; KLEBSIELLA PNEUMONIAE; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; ANTIBIOTIC RESISTANCE; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG EFFECT; GRAM NEGATIVE INFECTION; HUMAN; ISOLATION AND PURIFICATION;

ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS;

EID: 85029688287     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2017.09.001     Document Type: Review

References (106)

1. Pitout, J.D., Laupland, K.B., Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 8 (2008), 159–166.
2. WHO, Antimicrobial resistance global report on surveillance., 2014, World Health Organization, Geneva.
3. Chang, H.J., Hsu, P.C., Yang, C.C., Kuo, A.J., Chia, J.H., Wu, T.L., et al. Risk factors and outcomes of carbapenem-nonsusceptible Escherichia coli bacteremia: a matched case-control study. J Microbiol Immunol Infect 44 (2011), 125–130.
4. Falagas, M.E., Tansarli, G.S., Karageorgopoulos, D.E., Vardakas, K.Z., Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. Emerg Infect Dis 20 (2014), 1170–1175.
5. Falagas, M.E., Bliziotis, I.A., Kasiakou, S.K., Samonis, G., Athanassopoulou, P., Michalopoulos, A., Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria. BMC Infect Dis, 5, 2005, 24.
6. Sonnevend, A., Ghazawi, A., Hashmey, R., Haidermota, A., Girgis, S., Alfaresi, M., et al. Multi-hospital occurrence of pan-resistant Klebsiella pneumoniae ST147 with an ISEcp1-directed blaOXA-181 insertion into the mgrB gene in the United Arab Emirates. Antimicrob Agents Chemother, 61(7), 2017 Jun 27.
7. Weterings, V., Zhou, K., Rossen, J.W., van Stenis, D., Thewessen, E., Kluytmans, J., et al. An outbreak of colistin-resistant Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae in the Netherlands (July to December 2013), with inter-institutional spread. Eur J Clin Microbiol Infect Dis 34 (2015), 1647–1655.
8. WHO, Critically important antimicrobials for human medicine. 3rd ed., 2011, World Health Organization, Geneva Available at: http://apps.who.int/iris/ bitstream/10665/77376/1/9789241504485_eng.pdf?ua=1&ua=1.
9. Rafailidis, P.I., Falagas, M.E., Options for treating carbapenem-resistant Enterobacteriaceae. Curr Opin Infect Dis 27 (2014), 479–483.
10. ClinicalTrials.gov Multicenter open-label randomized controlled trial (RCT) to compare colistin alone versus colistin plus meropenem. Available at: https://clinicaltrials.gov/ct2/show/NCT01732250; accessed February 2017.
11. Nation, R.L., Garonzik, S.M., Thamlikitkul, V., Giamarellos-Bourboulis, E.J., Forrest, A., Paterson, D.L., et al. Dosing guidance for intravenous colistin in critically ill patients. Clin Infect Dis 62 (2016), 552–558.
12. Falagas, M.E., Vouloumanou, E.K., Samonis, G., Vardakas, K.Z., Fosfomycin. Clin Microbiol Rev 29 (2016), 321–347.
13. Karageorgopoulos, D.E., Miriagou, V., Tzouvelkis, L.S., Spyridopoulou, K., Daikos, G.L., Emergence of resistance to fosfomycin used as adjunct therapy in KPC Klebsiella pneumoniae bacteraemia: report of three cases. J Antimicrob Chemother 67 (2012), 2777–2779.
14. Bush, K., Page, M.G., What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles. J Pharmacokinet Pharmacodyn 44 (2017), 113–132.
15. Sader, H., Rhomberg, P., Flamm, R., Jones, R., Castanheira, M., WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases. J Antimicrob Chemother 72 (2017), 1696–1703.
16. Zhanel, G.G., Lawson, C.D., Adam, H., Schweizer, F., Zelenitsky, S., Lagace-Wiens, P.R., et al. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination. Drugs 73 (2013), 159–177.
17. Drawz, S.M., Papp-Wallace, K.M., Bonomo, R.A., New β-lactamase inhibitors: a therapeutic renaissance in an MDR world. Antimicrob Agents Chemother 58 (2014), 1835–1846.
18. Ehmann, D.E., Jahic, H., Ross, P.L., Gu, R.F., Hu, J., Kern, G., et al. Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor. Proc Natl Acad Sci U S A 109 (2012), 11663–11668.
19. Bush, K., A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens. Int J Antimicrob Agents 46 (2015), 483–493.
20. Castanheira, M., Mills, J.C., Costello, S.E., Jones, R.N., Sader, H.S., Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of β-lactamase-producing strains. Antimicrob Agents Chemother 59 (2015), 3509–3517.
21. Sader, H.S., Castanheira, M., Farrell, D.J., Flamm, R.K., Jones, R.N., Ceftazidime-avibactam activity when tested against ceftazidime-nonsusceptible Citrobacter spp., Enterobacter spp., Serratia marcescens, and Pseudomonas aeruginosa from Unites States medical centers (2011–2014). Diagn Microbiol Infect Dis 83 (2015), 389–394.
22. Flamm, R.K., Stone, G.G., Sader, H.S., Jones, R.N., Nichols, W.W., Avibactam reverts the ceftazidime MIC90 of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value. J Chemother 26 (2014), 333–338.
23. Walkty, A., DeCorby, M., Lagace-Wiens, P.R., Karlowsky, J.A., Hoban, D.J., Zhanel, G.G., In vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals (CANWARD 2009 study). Antimicrob Agents Chemother 55 (2011), 2992–2994.
24. Wang, X., Zhang, F., Zhao, C., Wang, Z., Nichols, W.W., Testa, R., et al. In vitro activities of ceftazidime-avibactam and aztreonam-avibactam against 372 Gram-negative bacilli collected in 2011 and 2012 from 11 teaching hospitals in China. Antimicrob Agents Chemother 58 (2014), 1774–1778.
25. Flamm, R.K., Sader, H.S., Farrell, D.J., Jones, R.N., Ceftazidime-avibactam and comparator agents tested against urinary tract isolates from a global surveillance program (2011). Diagn Microbiol Infect Dis 80 (2014), 233–238.
26. Li, H., Estabrook, M., Jacoby, G.A., Nichols, W.W., Testa, R.T., Bush, K., In vitro susceptibility of characterized β-lactamase-producing strains tested with avibactam combinations. Antimicrob Agents Chemother 59 (2015), 1789–1793.
27. Vasoo, S., Cunningham, S.A., Cole, N.C., Kohner, P.C., Menon, S.R., Krause, K.M., et al. In vitro activities of ceftazidime-avibactam, aztreonam-avibactam, and a panel of older and contemporary antimicrobial agents against carbapenemase-producing gram-negative bacilli. Antimicrob Agents Chemother 59 (2015), 7842–7846.
28. Humphries, R.M., Yang, S., Hemarajata, P., Ward, K.W., Hindler, J.A., Miller, S.A., et al. First report of ceftazidime-avibactam resistance in a KPC-3-expressing Klebsiella pneumoniae isolate. Antimicrob Agents Chemother 59 (2015), 6605–6607.
29. Shields, R.K., Clancy, C.J., Hao, B., Chen, L., Press, E.G., Iovine, N.M., et al. Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum β-lactamases, and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant K. pneumoniae. Antimicrob Agents Chemother 59 (2015), 5793–5797.
30. Levasseur, P., Girard, A.M., Claudon, M., Goossens, H., Black, M.T., Coleman, K., et al. In vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 56 (2012), 1606–1608.
31. Sader, H.S., Castanheira, M., Mendes, R.E., Flamm, R.K., Farrell, D.J., Jones, R.N., Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013. Antimicrob Agents Chemother 59 (2015), 3656–3659.
32. Sader, H.S., Castanheira, M., Flamm, R.K., Mendes, R.E., Farrell, D.J., Jones, R.N., Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia. Int J Antimicrob Agents 46910 (2015), 53–59.
33. Aktas, Z., Kayacan, C., Oncul, O., In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae. Int J Antimicrob Agents 39 (2012), 86–89.
34. Mazuski, J.E., Gasink, L.B., Armstrong, J., Broadhurst, H., Stone, G.G., Rank, D., et al. Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program. Clin Infect Dis 62 (2016), 1380–1389.
35. Wagenlehner, F.M., Sobel, J.D., Newell, P., Armstrong, J., Huang, X., Stone, G.G., et al. Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program. Clin Infect Dis 63 (2016), 754–762.
36. Carmeli, Y., Armstrong, J., Laud, P.J., Newell, P., Stone, G., Wardman, A., et al. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis 16 (2016), 661–673.
37. Shields, R.K., Potoski, B.A., Haidar, G., Hao, B., Doi, Y., Chen, L., et al. Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis 63 (2016), 1615–1618.
38. Gallagher, J.C., McKinnell, J., CAZAVI Compassionate Use Research Group. Compassionate use of ceftazidime/avibactam (Cazavi) for carbapenem-resistant (Cr) Gram-negative rod infections. Abst 428. Abst ASM Microbe. Am Soc Microbiol, June 17, 2016 Boston MA, USA.
39. Temkin, E., Torre-Cisneros, J., Beovic, B., Benito, N., Giannella, M., Gilarranz, R., et al. Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms. Antimicrob Agents Chemother, 61(2), 2017.
40. Shields, R.K., Nguyen, M.H., Chen, L., Press, E.G., Potoski, B.A., Marini, R.V., et al. Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother, 61, 2017 e00883–e17.
41. Livermore, D.M., Warner, M., Mushtaq, S., Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa. J Antimicrob Chemother 68 (2013), 2286–2290.
42. Lapuebla, A., Abdallah, M., Olafisoye, O., Cortes, C., Urban, C., Landman, D., et al. Activity of imipenem with relebactam against Gram-negative pathogens from New York City. Antimicrob Agents Chemother 59 (2015), 5029–5031.
43. Thaden, J.T., Poque, J.M., Kaye, K.S., Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae. Virulence 6 (2016), 1–14.
44. Lucasti, C., Vasile, L., Sandesc, D., Venskutonis, D., McLeroth, P., Lala, M., et al. Phase 2, Dose-ranging study of relebactam with imipenem-cilastatin in subjects with complicated intra-abdominal infection. Antimicrob Agents Chemother 60 (2016), 6234–6243.
45. ClinicalTrials.gov. Imipenem/relebactam/cilastatin versus piperacillin/tazobactam for treatment of participants with bacterial pneumonia (MK-7655A-014) (RESTORE-IMI 2). Available at: https://clinicaltrials.gov/ct2/show/NCT02493764; accessed February 2017.
46. ClinicalTrials.gov. Efficacy and safety of imipenem+cilastatin/relebactam (mk-7655a) versus colistimethate sodium + imipenem+cilastatin in imipenem-resistant bacterial infection (MK-7655A-013) (RESTORE-IMI 1). Available at: https://clinicaltrials.gov/ct2/show/NCT02452047 accessed February 2017.
47. Hecker, S.J., Reddy, K.R., Totrov, M., Hirst, G.C., Lomovskaya, O., Griffith, D.C., et al. Discovery of a cyclic boronic acid β-lactamase inhibitor (RPX7009) with utility vs class a serine carbapenemases. J Med Chem 58 (2015), 3682–3692.
48. Lapuebla, A., Abdallah, M., Olafisoye, O., Cortes, C., Urban, C., Quale, J., et al. Activity of meropenem combined with RPX7009, a novel β-lactamase inhibitor, against Gram-negative clinical isolates in New York City. Antimicrob Agents Chemother 59 (2015), 4856–4860.
49. Livermore, D.M., Mushtaq, S., Activity of biapenem (RPX2003) combined with the boronate β-lactamase inhibitor RPX7009 against carbapenem-resistant Enterobacteriaceae. J Antimicrob Chemother 68 (2013), 1825–1831.
50. Stus V, Sagan O, Bidair M, Loutit J, Dudley M et al. Meropenem-vaborbactam (M-V) versus piperacillin-tazobactam (P-T) in the treatment of adults with complicated urinary tract infections (cUTI), including acute pyelonephritis (AP) in TANGO 1, a phase 3 randomized, double-blind, double-dummy trial. Presented at 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna April 2017.
51. ClinicalTrials.gov. Efficacy, Safety, Tolerability of Carbavance Compared to Best Available Therapy in Serious Infections Due to Carbapenem Resistant Enterobacteriaceae, in Adults. Available at: https://clinicaltrials.gov/ct2/show/NCT02168946; accessed February 2017.
52. http://www.themedicinescompany.com/investors/news/medicines-company-announces-tango-2-trial-meropenem-vaborbactam-formerly-carbavance accessed August 2017.
53. Jacoby, G.A., Han, P., Detection of extended-spectrum β-lactamases in clinical isolates of Klebsiella pneumoniae and Escherichia coli. J Clin Microbiol 34 (1996), 908–911.
54. Yigit, H., Queenan, A.M., Rasheed, J.K., Biddle, J.W., Domenech-Sanchez, A., Alberti, S., et al. Carbapenem-resistant strain of Klebsiella oxytoca harboring carbapenem-hydrolyzing β-lactamase KPC-2. Antimicrob Agents Chemother 47 (2003), 3881–3889.
55. Yoshizumi, A., Ishii, Y., Aoki, K., Testa, R., Nichols, W.W., Tateda, K., In vitro susceptibility of characterized β-lactamase-producing Gram-negative bacteria isolated in Japan to ceftazidime-, ceftaroline-, and aztreonam-avibactam combinations. J Infect Chemother 21 (2015), 148–151.
56. Biedenbach, D.J., Kazmierczak, K., Bouchillon, S.K., Sahm, D.F., Bradford, P.A., In vitro activity of aztreonam-avibactam against a global collection of Gram-negative pathogens from 2012 and 2013. Antimicrob Agents Chemother 59 (2015), 4239–4248.
57. Kazmierczak, K.M., Biedenbach, D.J., Hackel, M., Rabine, S., de Jonge, B.L., Bouchillon, S.K., et al. Global dissemination of blaKPC into bacterial species beyond Klebsiella pneumoniae and in vitro susceptibility to ceftazidime-avibactam and aztreonam-avibactam. Antimicrob Agents Chemother 60 (2016), 4490–4500.
58. ClinicalTrials.gov. Determine the PK and safety and tolerability of ATM-AVI for the treatment of ciais in hospitalized adults (REJUVENATE). 2016. Available at: https://clinicaltrials.gov/ct2/show/NCT02655419; accessed February 2017.
59. Marshall, S., Hujer, A.M., Rojas, L.J., Papp-Wallace, K.M., Humphries, R.M., Spellberg, B., et al. Can ceftazidime-avibactam and aztreonam overcome β-lactam resistance conferred by metallo-β-lactamases in Enterobacteriaceae?. Antimicrob Agents Chemother 61 (2017), 2243–2316.
60. Davido, B., Fellous, L., Lawrence, C., Maxime, V., Rottman, M., Dinh, A., Ceftazidime-Avibactam and Aztreonam an interesting strategy to Overcome Β-lactam Resistance Conferred by Metallo-β-lactamases in Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother, 61(9), 2017 Aug 24.
61. Mojica, M.F., Ouellette, C.P., Leber, A., Becknell, M.B., Ardura, M.I., Perez, F., et al. successful treatment of bloodstream infection due to metallo-β-lactamase-producing Stenotrophomonas maltophilia in a renal transplant patient. Antimicrob Agents Chemother 60 (2016), 5130–5140.
62. Zhanel, G.G., Chung, P., Adam, H., Zelenitsky, S., Denisuik, A., Schweizer, F., et al. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Drugs 74 (2014), 31–51.
63. Takeda, S., Nakai, T., Wakai, Y., Ikeda, F., Hatano, K., In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa. Antimicrob Agents Chemother 51 (2007), 826–830.
64. Cabot, G., Bruchmann, S., Mulet, X., Zamorano, L., Moya, B., Juan, C., et al. Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC. Antimicrob Agents Chemother 58 (2014), 3091–3099.
65. Juan, C., Zamorano, L., Perez, J.L., Ge, Y., Oliver, A., Spanish Group for the Study of P, et al. Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. Antimicrob Agents Chemother 54:2 (2010), 846–851.
66. Sader, H.S., Rhomberg, P.R., Farrell, D.J., Jones, R.N., Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes. Antimicrob Agents Chemother 55 (2011), 2390–2394.
67. Sader, H.S., Farrell, D.J., Castanheira, M., Flamm, R.K., Jones, R.N., Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011–12). J Antimicrob Chemother 69 (2014), 2713–2722.
68. Pfaller, M.A., Bassetti, M., Duncan, L.R., Castanheira, M., Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012–15). J Antimicrob Chemother 72 (2017), 1386–1395.
69. Estabrook, M., Bussell, B., Clugston, S.L., Bush, K., In vitro activity of ceftolozane-tazobactam as determined by broth dilution and agar diffusion assays against recent U.S. Escherichia coli isolates from 2010 to 2011 carrying CTX-M-type extended-spectrum β-lactamases. J Clin Microbiol 52 (2014), 4049–4052.
70. Solomkin, J., Hershberger, E., Miller, B., Popejoy, M., Friedland, I., Steenbergen, J., et al. Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI). Clin Infect Dis 60 (2015), 1462–1471.
71. Wagenlehner, F.M., Umeh, O., Steenbergen, J., Yuan, G., Darouiche, R.O., Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet 385:9981 (2015), 1949–1956.
72. Huntington, J.A., Sakoulas, G., Umeh, O., Cloutier, D.J., Steenbergen, J.N., Bliss, C., et al. Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial. J Antimicrob Chemother 71 (2016), 2014–2021.
73. Popejoy, M.W., Paterson, D.L., Cloutier, D., Huntington, J.A., Miller, B., Bliss, C.A., et al. Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials. J Antimicrob Chemother 72 (2017), 268–272.
74. ClinicalTrials.gov. Safety and efficacy study of ceftolozane/tazobactam to treat ventilated nosocomial pneumonia (ASPECT-NP). Available at: www.clinicaltrials.gov/ ct2/show/NCT0207075; accessed February 2017.
75. Munita, J.M., Aitken, S.L., Miller, W.R., Perez, F., Rosa, R., et al. Multicenter evaluation of ceftolozane/tazobactam for serious infections caused by carbapenem-resistant Pseudomonas aeruginosa. Clin Infect Dis, 2017, 10.1093/cid/cix014 cix014.
76. Page, M.G., Dantier, C., Desarbre, E., In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. Antimicrob Agents Chemother 54 (2010), 2291–2302.
77. Hofer, B., Dantier, C., Gebhardt, K., Desarbre, E., Schmitt-Hoffmann, A., Page, M.G., Combined effects of the siderophore monosulfactam BAL30072 and carbapenems on multidrug-resistant Gram-negative bacilli. J Antimicrob Chemother 68 (2013), 1120–1129.
78. Mushtaq, S., Woodford, N., Hope, R., Adkin, R., Livermore, D.M., Activity of BAL30072 alone or combined with β-lactamase inhibitors or with meropenem against carbapenem-resistant Enterobacteriaceae and non-fermenters. J Antimicrob Chemother 68 (2013), 1601–1608.
79. http://www.basilea.com/Portfolio/Portfolio/, accessed February 2017.
80. Mollmann, U., Heinisch, L., Bauernfeind, A., Kohler, T., Ankel-Fuchs, D., Siderophores as drug delivery agents: application of the “Trojan Horse” strategy. Biometals 22 (2009), 615–624.
81. Ito, A., Kohira, N., Bouchillon, S.K., West, J., Rittenhouse, S., Sader, H.S., et al. In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria. J Antimicrob Chemother 71 (2016), 670–677.
82. Kohira, N., West, J., Ito, A., Ito-Horiyama, T., Nakamura, R., Sato, T., et al. In vitro antimicrobial activity of a siderophore cephalosporin, S-649266, against Enterobacteriaceae clinical isolates, including carbapenem-resistant strains. Antimicrob Agents Chemother 60 (2016), 729–734.
83. Ito-Horiyama, T., Ishii, Y., Ito, A., Sato, T., Nakamura, R., Fukuhara, N., et al. Stability of novel siderophore cephalosporin S-649266 against clinically relevant carbapenemases. Antimicrob Agents Chemother 60 (2016), 4384–4386.
84. Portsmouth S, Vennhuyzen D, Echols R, Machida M, Ferrreira JCA, et al. Cefiderocol compared with imipenem/cilastatin in the treatment of adults with complicated urinary tract infections with or without pyelonephritis or acute uncomplicated pyelonephritis: results from a multicentre, double-blind, randomized study. Presented at 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna April 2017.
85. ClinicalTrials.gov. Study of S-649266 or best available therapy for the treatment of severe infections caused by carbapenem-resistant Gram-negative pathogens (CREDIBLE – CR). Available at: https://clinicaltrials.gov/ct2/show/NCT02714595?term=649266&rank=2; accessed February 2017.
86. Aggen, J.B., Armstrong, E.S., Goldblum, A.A., Dozzo, P., Linsell, M.S., Gliedt, M.J., et al. Synthesis and spectrum of the neoglycoside ACHN-490. Antimicrob Agents Chemother 54 (2010), 4636–4642.
87. Livermore, D.M., Mushtaq, S., Warner, M., Zhang, J.C., Maharjan, S., Doumith, M., et al. Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. J Antimicrob Chemother 66 (2011), 48–53.
88. Galani, I., Souli, M., Daikos, G.L., Chrysouli, Z., Poulakou, G., Psichogiou, M., et al. Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece. J Chemother 24 (2012), 191–194.
89. Almaghrabi, R., Clancy, C.J., Doi, Y., Hao, B., Chen, L., Shields, R.K., et al. Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents. Antimicrob Agents Chemother 58 (2014), 4443–4451.
90. Walkty, A., Adam, H., Baxter, M., Denisuik, A., Lagace-Wiens, P., Karlowsky, J.A., et al. In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in Canadian hospitals as part of the CANWARD study, 2011–2012. Antimicrob Agents Chemother 58 (2014), 2554–2563.
91. Garcia-Salguero, C., Rodriguez-Avial, I., Picazo, J.J., Culebras, E., Can plazomicin alone or in combination be a therapeutic option against carbapenem-resistant Acinetobacter baumannii?. Antimicrob Agents Chemother 59 (2015), 5959–5966.
92. http://www.achaogen.com/media-all/2012/5/15/achaogen-announces-all-objectives-met-in-phase-2-plazomicin-complicated-urinary-tract-infections-study-and-start-of-first-in-human-study-with-achn-975.
93. Cloutier D, Miller L, Komirenko A, Cebrik D, Krause et al. Plazomicin versus meropenem for the treatment of complicated urinary tract infection (cUTI) and acute pyelonephritis (AP): results of the EPIC study. Presented at 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna April 2017.
94. Connolly LE, Jubb AM, O'Keeffe B, Serio AW, Smith A, Gall J, et al. Plazomicin associated with improved survival and safety compared with colistin in serious carbapenem-resistant Enterobacteriaceae (CRE) infections: results of the CARE Study. Presented at ASM Microbe, New Orleans June 2017.
95. Zhanel, G.G., Cheung, D., Adam, H., Zelenitsky, S., Golden, A., Schweizer, F., et al. Review of eravacycline, a novel fluorocycline antibacterial agent. Drugs 76 (2016), 567–588.
96. Bassetti, M., Righi, E., Eravacycline for the treatment of intra-abdominal infections. Expert Opin Investig Drugs 23 (2014), 1575–1584.
97. Sutcliffe, J.A., O'Brien, W., Fyfe, C., Grossman, T.H., Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob Agents Chemother 57 (2013), 5548–5558.
98. Grossman, T.H., Starosta, A.L., Fyfe, C., O'Brien, W., Rothstein, D.M., Mikolajka, A., et al. Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic. Antimicrob Agents Chemother 56 (2012), 2559–2564.
99. Abdallah, M., Olafisoye, O., Cortes, C., Urban, C., Landman, D., Quale, J., Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City. Antimicrob Agents Chemother 59 (2015), 1802–1805.
100. Zhang, Y., Lin, X., Bush, K., In vitro susceptibility of β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE) to eravacycline. J Antibiot (Tokyo) 69 (2016), 600–604.
101. Livermore, D.M., Mushtaq, S., Warner, M., Woodford, N., In vitro activity of eravacycline against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii. Antimicrob Agents Chemother 60 (2016), 3840–3844.
102. Solomkin, J., Evans, D., Slepavicius, A., Lee, P., Marsh, A., Tsai, L., et al. Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the investigating gram-negative infections treated with eravacycline (IGNITE 1) trial: a randomized clinical trial. JAMA Surg 152 (2016), 224–232.
103. Tetraphase announces top-line results from IGNITE2 phase 3 clinical trial of eravacycline in cuti. Available at: http://ir.tphase.com/releasedetail.cfm?releaseid=930613; accessed February 2017.
104. Prasad, P., Sun, J., Danner, R.L., Natanson, C., Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis 54 (2012), 1699–1709.
105. Shen, F., Han, Q., Xie, D., Fang, M., Zeng, H., Deng, Y., Efficacy and safety of tigecycline for the treatment of severe infectious diseases: an updated meta-analysis of RCTs. Int J Infect Dis 39 (2015), 25–33.
106. Falagas, M.E., Mavroudis, A.D., Vardakas, K.Z., The antibiotic pipeline for multi-drug resistant gram negative bacteria: what can we expect?. Expert Rev Anti Infect Ther 14 (2016), 747–763.